A Review of Emerging ARNI Data in HFrEF
Published: 27 November 2019
3m 33sPart 2 Commentary on ARIADNE
6m 57sPart 3 PROVE-HF in Review
8m 25sPart 4 EVALUATE in Review
6m 30sPart 6 TRANSITION-CHF in Review
5m 40sPart 7 PIONEER in Review
Despite advances in cardiovascular therapy, heart failure (HF) continues to be a leading cause of morbidity and mortality with significant cost to the health care system. Evidence for the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan has demonstrated significant reductions in all-cause mortality, cardiovascular mortality, and HF hospitalization compared with enalapril and international guidelines currently recommend its use.
Despite this evidence and the recommendation of clinical guidelines, ARNI therapy is not initiated in the majority of eligible patients. Evidence suggests a lack of understanding of a patient’s risk and also the benefit of life saving therapies by physicians is a primary cause of under-utilization.
Increased education is needed so clinicians fully understand the patient’s risk, as well as latest mechanistic and clinical data to ensure confidence in using newer therapies.
This educational program summarises new data covering ARNI therapy for heart failure with reduced ejection fraction (HFrEF) presented at the European Society of Cardiology (ESC) 2019 congress.
- Review updated data of ARNI therapy for HFrEF present at the ESC 2019
- Understand the current utilisation of ARNI therapy in HFrEF (guidelines and databases)
- Interpret potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data
- Apply new data covering the utilization of ARNI therapy in complex patients including recently decompensated and hospitalized patients.
More from this programme
ARIADNE in Review
|ARIADNE in Review||Watch now|
Commentary on ARIADNE
|Commentary on ARIADNE||Watch now|
PROVE-HF in Review
|PROVE-HF in Review||Watch now|
EVALUATE in Review
|EVALUATE in Review||Watch now|
Commentary on PROVE-HF and EVALUATE
|Commentary on PROVE-HF and EVALUATE||Watch now|
TRANSITION-CHF in Review
|TRANSITION-CHF in Review||Watch now|
PIONEER in Review
|PIONEER in Review||Watch now|
Commentary on TRANSITION-CHF and PIONEER
Professor Uwe Zeymer is an interventional cardiologist at the Klinikum Ludwigshafen (Germany). His interests include acute cardiac care and acute coronary syndromes.